Quantcast

Latest Bicalutamide Stories

2013-03-18 20:42:21

Sanford-Burnham researchers discover that a protein called Siah2 helps prostate cancer cells resist hormone therapy -- ;making it an attractive biomarker and therapeutic target Hormonal therapies can help control advanced prostate cancer for a time. However, for most men, at some point their prostate cancer eventually stops responding to further hormonal treatment. This stage of the disease is called androgen-insensitive or castration-resistant prostate cancer. In a study published March...

2013-02-11 15:53:09

Prostate cancer in younger patients is triggered by a different mechanism than in older men While prostate cancer is the most common cancer in elderly Western men it also, but more rarely, strikes patients aged between 35 and 50. Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, in collaboration with several other research teams in Germany, have discovered that such early-onset prostate cancers are triggered by a different mechanism from that which...

2012-04-04 09:26:44

Patients with castration-resistant prostate cancer treated with the androgen inhibitor abiraterone and who had high baseline hormone levels had longer overall survival compared with patients with low hormone levels, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4. If confirmed, these data mean that levels of hormones, specifically adrenal androgens, may provide physicians with another way to predict the efficacy of therapy in patients with...

2012-03-28 08:33:49

Androgen suppression — the inhibition of testosterone and other male hormones — is a routine therapy for prostate cancer. Unfortunately, it can dramatically reduce the quality of patients' sex lives and, more importantly, lead to cancer recurrence in a more deadly androgen-independent form. A new paper combining mathematical modeling with clinical data validates a different approach: cycling patients on and off treatment. Such intermittent androgen suppression alleviates most...

2012-02-01 10:22:54

Drug compound designed and developed in academic research lab A new drug, MDV3100, is improving the survival rate in men with advanced prostate cancer, results of a large, phase III clinical trial show. The drug is designed to block a type of cellular receptor that drives progression of prostate cancer. Based on the strength of the data from the phase III trial, it is anticipated that the biopharmaceutical company Medivation, which licensed MDV3100, will file a new drug application with...

2011-06-22 16:12:52

Homosexual men taking bicalutamide for prostate cancer were much more likely to report sexual problems during treatment than heterosexual patients, according to a study in the July issue of the urology journal BJUI. Researchers from Romania and the USA studied 17 heterosexual men and 12 homosexual men receiving a 50mg daily dose of bicalutamide, a fast-acting, non-steroidal anti-androgen, which is similar to other anti-androgens, but with reportedly fewer side effects. They discovered that...

2010-11-29 15:05:00

SAN FRANCISCO and TOKYO, Nov. 29, 2010 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. today announced that patient enrollment was completed on November 15, 2010 in the Phase 3 AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral androgen receptor antagonist, in patients with advanced prostate cancer who have previously been treated with chemotherapy. The companies also announced that clinical development of MDV3100 in Japan has...

2010-09-29 07:00:00

SAN FRANCISCO and TOKYO, Sept. 29 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. today announced treatment of the first patient in a second Phase 3 clinical trial of the investigational drug MDV3100, which expands the Phase 3 development of the novel, triple-acting oral androgen receptor antagonist into an earlier-stage patient population. Known as PREVAIL, the trial will evaluate MDV3100 in men with advanced prostate cancer who have not yet received...

2010-06-01 08:00:00

SAN FRANCISCO, June 1 /PRNewswire/ -- Prostate cancer patients on leuprolide who were offered to continue on FIRMAGON® (degarelix for injection) after one year of treatment reduced prostate specific antigen (PSA) recurrence, according to results of a Phase III extension study(1) presented here at the American Urological Association 2010 meeting. PSA is commonly used in monitoring prostate cancer patients' treatment response, and a high PSA number may indicate prostate...

2010-04-22 07:00:00

SAN DIEGO, April 22 /PRNewswire/ -- Aragon Pharmaceuticals Inc. today announced that it has secured $22 million in Series B financing. New investor Aisling Capital participated in the financing along with existing investors OrbiMed Advisors and The Column Group. The financing brings the total dollar amount raised to $30 million since the company's formation in May 2009. "Aragon is using a novel approach to create first-in-class and best-in-class drugs for hormonally driven cancers,"...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related